How Biotech Is Getting Berned By Presidential Contender Sanders
Presidential hopeful Bernie Sanders took the battle against high drug prices up a notch this week.
The Vermont senator and 11 other members of Congress sent letter to the National Institutes of Health (NIH) calling for hearings to discuss whether the agency should exercise its march-in patent rights to Medivation (NASDAQ:MDVN) and Astellas Pharma's (NASDAQOTH:ALPMY) Xtandi, a widely used prostate cancer drug.
The Vermont senator and 11 other members of Congress sent letter to the National Institutes of Health (NIH) calling for hearings to discuss whether the agency should exercise its march-in patent rights to Medivation (NASDAQ:MDVN) and Astellas Pharma's (NASDAQOTH:ALPMY) Xtandi, a widely used prostate cancer drug.